Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of clostridium difficile infection

Clinical Infectious Diseases

Volumn 54, Issue 4, 2012, Pages 568-574

  Venugopal, Anilrudh A ^a,b   Johnson, Stuart ^c,d  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

AGAR DILUTION; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACILLUS SUBTILIS; BACTERIAL STRAIN; BACTEROIDES FRAGILIS; BROTH DILUTION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM PERFRINGENS; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INHIBITION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROCOCCUS AVIUM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FECES MICROFLORA; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERURICEMIA; LIMIT OF QUANTITATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG APPROVAL; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856718514     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir830     Document Type: Review

References (38)

1. Bartlett JG. Antibiotic-associated colitis. Dis Mon 1984; 30:1-54.
2. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9. (Pubitemid 41770165)
3. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41. (Pubitemid 41770164)
4. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J 2004; 171:466-72. (Pubitemid 39179608)
5. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Cont Hosp Ep 2010; 31:431-55.
6. Louie T, Gerson M, Grimmard D, et al. Results of a phase III trial comparing tolevamer, vancomycin, and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society for Microbiology, 2007.
7. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7. (Pubitemid 47101025)
8. Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24:324-33. (Pubitemid 27096783)
9. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficileassociated diarrhoea and colitis. Lancet 1983; 2:1043-6. (Pubitemid 14235361)
10. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758-64. (Pubitemid 43363928)
11. Dificid-(fidaxomicin) tablets [Prescribing Information]. San Diego, CA: Optimer Pharmaceuticals, Inc., 2011; Available at: http://www. dificid.com/upload/dificid.pdf. Accessed 8 June 2011.
12. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Ch 2009; 53:223-8.
13. Anti-Infective Drugs Advisory Committee Briefing Document, Optimer Pharmaceuticals, Inc. Dificid-(fidaxomicin tablets) for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficileassociated diarrhea (CDAD), and for reducing the risk of recurrence when used for treatment of initial CDI. 1-128. 4-4-2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/ Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM249354.pdf. Accessed 8 June 2011.
14. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Ch 2008; 52:1391-5. (Pubitemid 351522003)
15. Chopra I. Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents. Curr Opin Investig Drugs 2007; 8:600-7. (Pubitemid 47205244)
16. Coronelli C, White RJ, Lancini GC, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. J Antibiot (Tokyo) 1975; 28:253-9.
17. Gualtieri M, Villain-Guillot P, Latouche J, Leonetti JP, Bastide L. Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin. Antimicrob Agents Ch 2006; 50:401-2. (Pubitemid 43042959)
18. Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Ch 1991; 35:1108-11.
19. Miller M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother 2010; 11:1569-78.
20. Sergio S, Pirali G, White R, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanismof action. J Antibiot (Tokyo) 1975; 28:543-9.
21. Louie TJ, MillerMA,Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
22. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Ch 2004; 48:4430-4. (Pubitemid 39434908)
23. Finegold SM, Molitoris D, Vaisanen ML, Song Y, Liu C, Bolanos M. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Ch 2004; 48:4898-02.
24. Theriault RJ, Karwowski JP, Jackson M, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J Antibiot (Tokyo) 1987; 40:567-74. (Pubitemid 17072152)
25. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Ch 2009; 53:261-3.
26. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156:3354-9.
27. Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Ch 2004; 48:2280-2. (Pubitemid 38691631)
28. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Ch 2007; 51:2716-19. (Pubitemid 47206204)
29. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Ch 2008; 52:4163-5.
30. Citron DM, Babakhani F, Goldstein EJ, et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009; 15:234-6.
31. Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection. Antimicrob Agents Ch 2011; 55:5194-99.
32. Babakhani F, Gomez A, Robert N, Sears P. Killing kinetics of fidaxomicin and its major metabolite (OP-1118) against Clostridium difficile. J Med Microbiol 2011; 60:1213-17.
33. Kurabachew M, Lu SH, Krastel P, et al. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Ch 2008; 62:713-19.
34. Babakhani F, Gomez A, Robert N, Sears P. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Ch 2011; 55:4427-9.
35. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Ch 2008; 52:2813-17.
36. Crook D, Weiss K, Cornerly O, et al. Randomized clinical trial (RCT) in Clostridium difficile infection (CDI) confirms equivalent cure rate and lower recurrence rate of fidaxomicin (FDX) versus vancomycin (VCN). In: Program and abstracts of the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). (Vienna, Austria). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases, 10-13 April 2010.
37. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53:440-7.
38. Patrella LA, Sambol S, Nagaro K, et al. Multivariate analysis of C. difficile infection (CDI) outcomes in epidemic BI-associated cases treated with fidaxomicin or vancomycin. In: Program and abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society for Microbiology, 17-20 September 2011.